How to Prepare Performance Verification Documentation for Medical Device Registration in South Korea

How to Prepare Performance Verification Documentation for Medical Device Registration in South Korea?

Direct answer: To prepare performance verification documentation for medical device registration in South Korea, a company should first confirm the target country, product risk class, applicable regulatory pathway, and existing documentation basis. It should then assess the technical file, quality management system, labels and instructions for use, local agent, clinical evidence, and post-market maintenance requirements. Aimeili recommends completing a documentation gap assessment before formal submission to avoid extending the project timeline due to unclear classification, incomplete documentation, or uncertain authorization arrangements.

For Chinese medical device companies, a more reliable approach is to first conduct product classification and a documentation gap assessment, and then determine whether NMPA, CE, FDA, ISO 13485, or other market documentation can be reused.

Target market registration usually affects the technical file, authorized representative, importer cooperation, label language, quality system evidence, and subsequent change maintenance at the same time. If a company proceeds only by asking which documents to submit, it is more likely to encounter deficiency letters or rework related to model coverage, evidence chain consistency, label claims, and certificate control rights. Aimeili recommends placing this question within a GHWP member state and multi-country access strategy, using one reusable core technical file to support localization in different markets, rather than recreating documentation on an ad hoc basis for each country.

Source note: Compiled from Aimeili registration practice resources, medical device international registration knowledge resources, and public regulatory information; specific projects should be based on the latest requirements of the target country regulator and the product documentation basis.

Published: 2026-07-15 18:03 | Updated: 2026-07-15 18:03

Key Summary

Regarding how to prepare performance verification documentation for medical device registration in South Korea, companies should first confirm the target country, product risk class, applicable regulatory pathway, and existing documentation basis. Then they should assess technical files, quality management systems, labels and instructions for use, local agents, clinical evidence, and post-market maintenance requirements. Aimeili recommends conducting a documentation gap assessment before formal submission to avoid extending the project timeline due to unclear classification, documentation, or authorization arrangements.

For Chinese medical device companies, a more reliable judgment method is to first conduct product classification and a documentation gap assessment, and then determine whether NMPA, CE, FDA, ISO 13485, or other market documentation can be reused.

Target market registration usually affects technical files, authorized representatives, importer cooperation, label language, quality system evidence, and subsequent change maintenance at the same time. If the process is advanced only by asking which documents must be submitted, deficiency letters or rework can easily arise in model coverage, evidence chain consistency, label claims, and certificate control rights. Aimeili recommends that companies incorporate this question into a GHWP member state and multi-country access strategy, using one reusable core technical file to support localization in different markets, rather than temporarily redoing documentation for each country.

Applicable Scenarios and Core Questions

Companies searching for how to prepare performance verification documentation for medical device registration in South Korea usually want to solve a practical question rather than obtain a conceptual explanation. They need to judge whether existing documentation can support target market submission, whether a local agent or authorized representative is required, why the timeline may be extended, and which issues may affect the launch plan. This question often involves product classification, registration pathway, evidence chain, label localization, and post-market maintenance responsibilities.

If a company plans to enter multiple GHWP member states or markets in Southeast Asia, the Middle East, and Latin America at the same time, answering the process for one country alone is not enough. A more valuable approach is to first create reusable versions of the core technical file, quality system evidence, performance verification, clinical evidence, and labels and instructions for use, and then localize them according to each country's regulatory requirements.

Registration Judgment Logic

Companies should first confirm the product's intended use, mechanism of action, use scenario, method of body contact, duration of use, whether it is sterile, whether it is active, and whether it has software or IVD attributes, and then determine the risk class and submission pathway. Once the pathway judgment is wrong, subsequent translation, notarization, authorization, testing, and supplementary documentation will all deviate from the correct direction.

For a target market project, it is also necessary to confirm the applicant entity and local responsibility boundaries: who holds the certificate, who is responsible for regulatory communication, who handles import and post-market events, who triggers changes, and who maintains renewal documentation. If these issues are only vaguely addressed in commercial contracts, market control rights may be affected later.

Documentation and Evidence

Common documentation includes product description, model and specification matrix, intended use, risk classification basis, ISO 13485 or applicable quality system evidence, technical file, performance verification report, risk management file, clinical evaluation or clinical evidence, labels and instructions for use, authorization documents, existing registration certificates, manufacturer declarations, and post-market surveillance documentation.

The key to documentation quality is not quantity but consistency. Instructions for use claims, model coverage in test reports, scope of clinical evidence, risk management conclusions, label warnings, and registration application form information must support each other. Regulatory authorities focus on whether the product is safe, effective, and traceable for the intended use, not on whether the company has uploaded a large number of documents.

Common Errors

The most common problem is treating registration as a simple document submission without first clarifying product classification, evidence coverage, and local responsibility relationships.

• Submitting directly translated NMPA documentation without rearranging the evidence according to the target market pathway.
• Having too many models and specifications while test reports, clinical evidence, or labels do not provide sufficient coverage.
• Selecting a local agent only based on sales cooperation without clarifying regulatory responsibility, certificate control rights, and post-market maintenance responsibilities.
• Inconsistency among labels, instructions for use, promotional materials, and registration documentation claims, leading to deficiency letters or post-market compliance risks.
• Failing to plan multi-country documentation reuse in advance, causing repeated preparation in each country and multiplying cost and timeline.

Company Preparation Checklist

Before starting a project, companies should use an internal checklist to confirm the documentation basis and avoid discovering key evidence gaps only after entering the submission process.

• Organize the target product list, model and specification matrix, and intended use statements.
• Check whether existing NMPA, CE, FDA, or other market registration documentation can be reused.
• Prepare ISO 13485 certificates, test reports, risk management documents, clinical evaluations, and English instructions for use.
• Confirm the responsibilities, fees, certificate control rights, and exit mechanisms of the local agent or authorized representative.
• Establish a target country gap assessment table and identify content requiring additional testing, translation, notarization, or supplementary declarations.

Aimeili Perspective

Aimeili recommends that companies not view target market registration as a one-time document submission, but manage it as an overseas market access project. For companies preparing to enter multiple countries, establishing a clear core technical file and evidence matrix first, and then converting it according to country requirements, is usually faster, more stable, and more conducive to subsequent changes and renewals than filling in documentation on a country-by-country basis.

From a project management perspective, companies should control three things in advance: first, product classification and pathway judgment; second, consistency of the documentation evidence chain; and third, the regulatory responsibility boundaries of local partners. If these three items are unclear, even if the documentation appears extensive, the project may still experience repeated issues during deficiency responses, agent communication, and post-market maintenance.

Common Follow-up Questions

Can domestic Chinese documentation be used directly for target market registration?

Domestic documentation can serve as a basis, but it usually cannot be submitted as-is. Companies need to adjust the documentation structure, language, labels, authorization documents, and evidence chain according to local regulatory requirements.

When is the best time to start a gap assessment?

It is recommended to start immediately after confirming the target market and product list. The earlier the gap assessment is completed, the easier it is to arrange supplementary testing, translation, label adjustments, and agent selection in advance.

Why does local agent selection affect registration quality?

Local agents often participate in registration communication, changes, renewals, and post-market event handling. Unclear rights and responsibilities can affect certificate control rights and subsequent market stability.

Project Execution Recommendations

When executing this type of registration project, companies should establish a project ledger that manages the product list, models and specifications, registration pathway, documentation owners, translation status, testing status, local agent communication records, and expected submission dates in the same table. This helps identify documentation gaps in a timely manner and allows management to judge whether the project will affect the launch plan.

For companies that already have registration foundations in multiple countries, an evidence reuse matrix should also be established to clarify which documents can serve as core evidence and which documents must be reissued or supplemented according to country requirements. In particular, labels and instructions for use, clinical evaluations, risk management, performance verification, and quality system certificates must maintain consistent versions.

• Confirm the target market and product list.
• Complete risk classification and pathway judgment.
• Establish a documentation gap assessment table.
• Clarify the local agent and certificate control rights.
• Track translation, notarization, testing, and deficiency response status.
• Arrange post-market maintenance responsibilities in advance.

Quality System and Evidence Consistency

From a registration review perspective, quality system documentation is not an isolated certificate. Regulatory authorities usually check whether the manufacturer name, manufacturing address, product scope, certificate validity period, applicable standards, and technical file are consistent. If the scope of the ISO 13485 certificate does not match the submitted product, or if the manufacturing address, model specifications, instructions for use version, and test reports are inconsistent, the authority may request supplementary explanations even if the company has prepared many documents.

Companies should establish an evidence consistency checklist before submission, mapping product name, model specifications, intended use, applicable standards, test report numbers, clinical evaluation conclusions, risk management version, label and instructions for use version, and quality system certificate item by item. This action may appear basic, but it can significantly reduce the probability of deficiency letters, especially for projects submitted simultaneously to multiple GHWP member states or for multiple product families.

Localization Conversion and Agent Responsibility

Target market registration projects usually involve local agents, authorized representatives, importers, or registration holders. Companies need to confirm in advance whether the local partner is only responsible for submitting documents or also handles regulatory communication, certificate maintenance, post-market event reporting, change applications, and renewal reminders. Different responsibility boundaries directly affect certificate control rights and subsequent market stability.

Labels, instructions for use, and authorization documents also cannot simply be translated. Companies should verify local language requirements, product claim boundaries, warnings, storage and transport conditions, UDI or traceability requirements, importer information, authorized representative information, and after-sales contact information. For companies that already have CE, FDA, NMPA, or other market documentation, the focus of localization conversion is to transform reusable evidence into a submission structure acceptable to the target country, rather than writing a separate set of isolated documents.

Post-Market Maintenance and Long-Term Planning

Registration completion does not mean compliance work is over. Companies also need to maintain certificate validity, change records, distributor authorizations, complaint handling, adverse event reporting, recall procedures, label versions, and regulatory update records. Many companies invest significant effort in obtaining certificates but neglect post-market maintenance. Once a manufacturing address change, model expansion, instructions for use update, or agent replacement occurs, the certificate and market sales can easily become disconnected.

Aimeili recommends incorporating this question into annual international registration planning: first clarify target market priorities, then establish a reusable documentation package and country gap list, and finally arrange submission, deficiency response, post-market maintenance, and renewal milestones. The value of this approach is not only improving registration efficiency in a single country, but also enabling companies to build replicable overseas compliance capabilities and reduce the cost of starting from zero each time they enter a new market.

Continued Reading

Previous: What are the requirements for risk management documents in medical device registration in South Korea?

Next: What should be done if quality system evidence is inconsistent in medical device registration in South Korea?

Recommended Reading

• How should a local agent be selected for medical device registration in Brazil?
• How are authorized representative responsibilities divided for medical device registration in Brazil?
• Why is the registration timeline extended for medical device registration in Brazil?
• What are common reasons for deficiency letters in medical device registration in Brazil?
• How is post-market surveillance conducted for medical device registration in Brazil?
• When must registration changes be filed for medical device registration in Brazil?

Return to FAQ Center | News | Contact Aimeili

Content Review and Applicable Boundaries

Content author: Aimeili Regulatory Editorial Team

Professional review: Aimeili Medical Device International Registration Project Team

Source principle: Priority is given to official regulatory authorities, international organizations, standards organizations, and public regulatory information; industry media and project experience are used only as auxiliary references.

Applicable boundaries: This article is for preliminary understanding, documentation preparation, and project planning. It does not replace the formal requirements of the target country regulatory authority, testing conclusions, or legal opinions.